Showing 321-330 of 5059 results for "".
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- LIBERTY-CSU CUPID-C: Improved Itch in Spontaneous Chronic Urticaria with Dupliumabhttps://practicaldermatology.com/news/liberty-csu-cupid-c-improved-itch-in-spontaneous-chronic-urticaria-with-dupliumab/2485781/Dupilumab significantly reduced itch and hives severity in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite histamine 1–receptor antagonist (H1-AH) therapy, according to results from the phase 3 LIBERTY-CSU CUPID-C trial published
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- New Series Spotlights Real Stories of MCC Patientshttps://practicaldermatology.com/news/new-series-spotlights-real-stories-of-mcc-patients/2484808/The Skin Cancer Champions Community announced that it will launch its Living With: Merkel Cell Carcinoma (MCC) web series on Wednesday, January 14, 2026, from 12:00 to 1:00pm EST via Zoom. According to a release from the group, the premiere episode,
- Clascoterone 5% Solution Achieves Hair Regrowth in Large AGA Studyhttps://practicaldermatology.com/news/clascoterone-5-solution-acheives-hair-regrowth-in-large-aga-study/2484730/Cosmo Pharmaceuticals N.V. has reported phase 3 results from its two pivotal trials—Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)—evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). According t
- New Agreement Opens Premier Networks to TeleVox Techhttps://practicaldermatology.com/news/televox-and-premier-inc-announce-national-patient-engagement-agreement/2476115/TeleVox has announced a national group purchasing agreement with Premier, Inc. effective September 1, 2025, permiting Premier members to access negotiated pricing and terms for TeleVox offerings, including Digital Front Door, Appointment Management, Digital Care P
- SEEN Expands Pediatric Line with Fragrance-Free Baby Shampoo and Body Washhttps://practicaldermatology.com/news/seen-expands-pediatric-line-with-fragrance-free-baby-shampoo-and-body-wash/2474436/SEEN has announced the launch of SEEN Baby 2-in-1 Fragrance Free, a new ultra-gentle shampoo and body wash designed specifically for infants and young children with sensitive or eczema-prone skin, according to a news release from the manufacturer.
- New Tapinarof Data Promising for Children and Perhaps Morehttps://practicaldermatology.com/news/New-Tapinarof-Data-Promising-Children-Perhaps-More/2471623/An analysis of the Phase 3 ADORING 3 study evaluating tapinarof cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD) presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, demonstrated that AD disease activity re
- Further Positive Delgocitinib Data Presented at AADhttps://practicaldermatology.com/news/Further-Positive-Delgocitinib-Data-Presented-AAD/2471609/Late-breaking data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showcased responses in a subgroup of patients from the DELTA 1 and Delta 2 trials on lebrikizumab for chronic hand eczema. Alongside this presentation, new systemic exposure
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba